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Résumé Summary
Le cas de M. Andrew Gobea, le premier enfant à recevoir 
une  thérapie  génique  expérimentale  pour  le  déficience 
immunitaire combinée sévère (DICS), et une réflexion sur 
les  implications  éthiques  associées  à  la  recherche  en 
thérapie génique.
The  case  of  Andrew  Gobea,  the  first  child  to  receive 
experimental  gene  therapy  for  severe  combined 
immunodeficiency  (SCID),  and  a  reflection  on  the 
associated ethical implications of gene therapy research.
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This  case  study,  which  is  based  on  the  PBS  story  "A Genetic  Rescue  for  a  Tattered  Immune  
System?"[1],  was  initially  published  in  shorter  form  on  my  website,  Genethics.ca,  in  2002  
(http://genethics.ca/somatictherapy.html).
The Case 
Andrew Gobea was born in  1993 with  a rare,  normally  fatal  genetic  disease – severe combined 
immunodeficiency (SCID).[2] SCID – which can take various forms – destroys much of the immune 
system,  particularly  the  T  cells,  leaving  newborns  defenseless  against  infection.[3]  There  are  a 
number of causes for SCID, but, in Andrew’s case, he had two defective copies of the gene that codes 
for a critical enzyme, adenosine deaminase (ADA). Without the enzyme, the body fails to break down 
chemicals produced during normal metabolism that are toxic to T cells; and without T cells, there is no 
immunity, and with no immunity, death is inevitable.
A bone marrow transplant from a tissue-matched donor, usually a sibling, is the most common and 
effective treatment for SCID. Unfortunately, it is relatively rare that a person such as Andrew would 
find a matched donor, even within their family; as a result, they must be put on a waiting list to obtain  
a bone marrow transplant from an unrelated matched donor.[3] In 1993, however, a novel treatment – 
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experimental gene therapy – existed that offered the potential to keep Andrew alive. Working copies of 
the ADA gene would be inserted into the T cells, in cord blood stem cells, and then re-introduced into  
Andrew’s system. But Andrew’s condition meant that his stem cells also lacked a functioning ADA 
gene, so a modified virus would be used to insert a working ADA gene into these cells. The hope was 
that the virus would infect and then deposit the genes into enough cells to give Andrew a working 
immune system.
At only 4 days old, Andrew Gobea became the first baby to receive gene therapy using cord blood 
cells.[4] Some of the cells did indeed take up the gene and began producing T cells with a functioning 
ADA gene. To insure Andrew’s survival, though, he had to be given weekly injections of the missing 
ADA enzyme, at the time at a cost of $2,200US per dose. These injections worked to clear the toxic 
metabolites out of his blood stream and allow the uncorrected T cells to survive. When Andrew was 18 
months old, his doctor began tapering off the amount of enzyme in the injections, to see if the T cells 
that produce ADA could take over; and at four years old, he was cut off the enzyme altogether. For 
two months, things went well, but then Andrew caught a cold, which developed into a yeast infection 
of the mouth, something commonly found in immunocompromised patients. Andrew’s immune system 
was  crashing  and  it  was  necessary  to  resume  the  ADA treatment.  The  modified  genes  did  not 
succeed in getting integrated into a sufficient number of cells to maintain the effect, and thus Andrew 
continues to need regular enzyme doses. The challenge for future research would be to find ways to 
get more cells to take up their message and keep producing the enzymes or other proteins critical for 
a patient’s health.
Gene therapy for SCID again made the news in 2000, when two children in a clinical trial showed the  
development  of  functioning  immune systems.  But  the  clinical  trial  was stopped  when two of  the 
participants were found to have developed leukemia[5]. Ten years later – and 18 years since Andrew 
first  received his treatment – and the early hopes of gene therapy for SCID are starting to show 
promise; most of the children in two recent studies had functioning immune systems, re-igniting the 
hope that a cure for SCID is near.[6]
Questions to consider:
1. Is the time and money involved in gene therapy research worth the investment given the still  
relatively  low  success  rate  of  clinical  trials?  Should  such  economic  issues  not  be  a 
consideration? How would one decide?
2. Is experimental gene therapy ethically different from other novel treatments, in terms of how 
we should evaluate the balance of risks and benefits?
3. Does the potential benefit of gene therapy for SCID (or for other rare disease) to provide a 
permanent  cure  (instead  of  regular  treatment)  justify  the  risks  that  patients  take  (e.g.,  of 
developing leukemia, other cancers)?
4. What risks should Andrew, his family, and society at large consider with regards to the use of  
modified viruses as vectors for gene therapy?
5. Are families of children such as Andrew being given unreasonable hope that a cure is “around 
the corner” when they consent for their children to participate in clinical trials?
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